
|Articles|December 13, 2021
Current and Future Trends in Myelofibrosis: Cytopenias
This publication reviews challenges associated with the management of myelofibrosis and examines the current and future role of janus-associated kinase inhibitors in the evolving treatment landscape.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5




































